Does Inclisiran Maintain LDL-C Lowering in CKD? Phase 3 Pooled Data Suggest Consistent Efficacy Across eGFR Strata

In a patient with CKD and LDL-C above target despite a statin, when should I refer for non-statin intensification?

Optimise the statin first, then refer for non-statin add-on if LDL-C remains above target on maximal tolerated therapy or if escalation is limited by CKD severity/intolerance. In CKD, referral is more justified when the patient is very high ASCVD risk, has possible familial hypercholesterolaemia, or may need injectable

Does reduced eGFR change the inclisiran dose or the timing of lipid monitoring?

No — reduced eGFR does not require an inclisiran dose adjustment in mild, moderate, or severe renal impairment. The standard regimen remains inclisiran 284 mg subcutaneously on Day 1, at 3 months, then every 6 months. Inclisiran has not been studied in end-stage renal disease, so use there is less certain. Reduced eGFR

How should inclisiran be sequenced against ezetimibe and PCSK9 monoclonal antibodies in stage 3–4 CKD?

In stage 3–4 CKD (eGFR 15–59 mL/min/1.73 m²), I would generally sequence LDL-lowering therapy as: 1. Maximally tolerated statin first 2. Add ezetimibe 10 mg PO daily if LDL-C remains above goal or a further ~15–25% reduction is needed 3. Escalate to a PCSK9-targeting injectable if still above goal or if very high-risk

What LDL-C response after the loading phase should prompt review of adherence, administration, or secondary causes?

Assuming this refers to inclisiran after the initial loading phase (Day 1 and Day 90): an LDL-C reduction of <20% from baseline should prompt review of adherence, correct administration, and secondary causes of hypercholesterolaemia. This threshold is reflected in regulatory/label-style guidance for inclisiran and is c

Should incomplete cardiovascular outcomes data limit inclisiran use in very-high-risk patients with CKD?

No — incomplete cardiovascular outcomes data should not automatically preclude inclisiran use in very-high-risk CKD patients, but it should limit how strongly you prioritise it over therapies with proven event reduction. In practice, inclisiran is best viewed as an LDL-C–lowering option for selected patients who remain